Definium Therapeutics, Inc.
Stock
Stock
ISIN: CA24477V1058
Ticker: MNMD
CA24477V1058
MNMD
Price
Price
CHART BY
Frequently asked questions
What is Definium Therapeutics, Inc.'s market capitalization?
The market capitalization of Definium Therapeutics, Inc. is $1.16B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Definium Therapeutics, Inc.?
Definium Therapeutics, Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.972. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Definium Therapeutics, Inc.'s stock?
Currently, 13 analysts cover Definium Therapeutics, Inc.'s stock, with a consensus target price of $28.67. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Definium Therapeutics, Inc.?
Definium Therapeutics, Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$151.19M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Definium Therapeutics, Inc.?
Definium Therapeutics, Inc. has a free cash flow of -$113.88M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Definium Therapeutics, Inc. have, and what sector and industry does it belong to?
Definium Therapeutics, Inc. employs approximately 74 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
Financials
- Market Cap
- $1.16B
- EPS (TTM)
- -$1.972
- EBITDA (TTM)
- -$151.19M
- Free Cashflow (TTM)
- -$113.88M
Pricing
- 1D span
- $14.43$14.86
- 52W span
- $4.71$15.88
Analyst Ratings
The price target is $28.67 and the stock is covered by 13 analysts.
Buy
13
Hold
0
Sell
0
Information
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
- Employees
- 74
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- CA24477V1058
- Primary Ticker
- MNMD
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet